title: Lustra, Lustra-AF and Alustra.
abstract: Hydroquinone has been successfully used to treat hyperpigmentation disorders for many years. Recently, new formulations containing hydroquinone have become available, including Lustra and Lustra-AF (Medicis). These products also contain glycolic acid 2%, an active antioxidant system (ascorbyl palmitate and tocopherol acetate), and moisturizers. Lustra-AF also contains a broad-spectrum sunscreen. Alustra contains a stabilized, high-concentration of retinol. The above formulations inhibit melanogenesis, stimulate epidermal desquamation, inhibit free radical-mediated photodamage and restore the antioxidant reservoir. The addition of retinoids may facilitate epidermal penetration of hydroquinone and prevent its oxidation. Comparative studies have shown that these agents can be effective in reducing blotchiness, mottled hyperpigmentation, post-inflammatory hyperpigmentation, and surface roughness. In addition, these formulations have been generally well tolerated with patients rarely reporting mild-to-moderate adverse events such as dryness, redness, or peeling of the skin.
authors.affiliation: Department of Medicine, Sunnybrook and Women s College Health Science Centre (Sunnybrook Site) and the University of Toronto, Toronto, ON, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: J E
authors.initials: JE
authors.lastname: Ryder
mesh_terms: D004359:Drug Therapy, Combination; D006801:Humans; D006873:Hydroquinones / Q000008:administration & dosage* / Q000009:adverse effects; D017495:Hyperpigmentation / Q000188:drug therapy*; D008548:Melanosis / Q000188:drug therapy; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D006873:Hydroquinones; D014212:Tretinoin; C031927:hydroquinone